Biotech Archives - Page 784 of 795

1 minute read

Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS

July 12, 4:31 PM

Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data

ATRA

3 minute read

Renovacor Announces New Research Program For Multiple Genetic Segments Of Arrhythmogenic Cardiomyopathy

By Bill Haddad

July 12, 4:08 PM

Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments

RCOR

7 minute read

FDA
News

Vaxcyte Completes Enrollment Of Phase 2 Portion Of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability And Immunogenicity Of VAX-24 In Adults

By Benzinga Newsdesk

July 12, 4:06 PM

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- Company Expects to Announce Topline Results from the

PCVX

1 minute read

Synlogic Granted U.S. Patent Titled ‘BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION (INCLUDING BUT NOT LIMITED TO CELIAC DISEASE, CROHN’S DISEASE, MULTIPLE SCLEROSIS)’

By Benzinga Newsdesk

July 12, 3:43 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11384359&OS=11384359&RS=11384359

SYBX

1 minute read

Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew

By Vandana Singh

July 12, 2:54 PM

Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…

DYN

1 minute read

HC Wainwright Sees Agile Therapeutics’ Twirla Tailwinds Post Roe-Wade Ruling

By Vandana Singh

July 12, 2:33 PM

Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.

AGRX

1 minute read

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer’s Program

By Vandana Singh

July 12, 2:24 PM

Hoth Therapeutics Inc (NASDAQ:HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer’s disease mouse model. HT-ALZ…

HOTH

1 minute read

Analysts Cuts Price Target On MacroGenics – Read Why

By Vandana Singh

July 12, 1:56 PM

BMO Capital Markets downgraded MacroGenics Inc (NASDAQ:MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers. The…

MGNX

1 minute read

Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock

By Vandana Singh

July 12, 1:44 PM

BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…

FATE

3 minute read

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

By Zacks

July 12, 1:33 PM

Image sourced from Shutterstock